Paraneoplastic Antibodies (PCCA/ANNA) by IFA with Reflex to Titer and Immunoblot, CSF
Also known as: PCCAANNA C
Use
The test aids in diagnosing paraneoplastic neurologic syndromes associated with malignancy using cerebrospinal fluid (CSF) specimens. Paraneoplastic antibodies, like PCCA/ANNA, can act as markers to help differentiate true paraneoplastic neurological disorders (PND) from other inflammatory disorders of the nervous system. These antibodies may indicate specific underlying neoplasms associated with the patient's symptoms, guiding further clinical investigation.
Special Instructions
This test incorporates a reflex mechanism: if the IFA screen is indeterminate, an immunoblot is added, and if the IFA screen shows positivity at 1:1, a specific titer and immunoblot tests are subsequently added with additional charges. Ensure refrigeration of samples and avoid repeated freeze/thaw cycles to maintain specimen integrity.
Limitations
The test results are based on indirect detection methodologies, and false positives/negatives can occur. Stability is limited to specific conditions, and improper handling of specimens, such as contamination or hemolysis, may affect results. The methodological approach may not cover all antineuronal antibodies, and it has not been FDA-cleared or approved.
New York Approved
Methodology
Immunoassay (IHC)
Biomarkers
LOINC Codes
- 14247-1
Result Turnaround Time
1-6 days
Related Documents
For more information, please review the documents below
Specimen
Cerebrospinal Fluid
Volume
2 mL
Minimum Volume
0.75 mL
Container
ARUP standard transport tube
Storage Instructions
Refrigerated
Causes for Rejection
Contaminated, heat-inactivated, hemolyzed, or lipemic specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 24 hours |
| Refrigerated | 2 weeks |
| Frozen | 1 year (avoid repeated freeze/thaw cycles) |